Improving outcomes for women diagnosed with mucinous ovarian cancer

Grant number: 1045783 | Funding period: 2013 - 2016

Completed

Abstract

Mucinous ovarian cancer (MOC) is different from other ovarian cancers but few studies have characterized the genetic changes specific to this subtype. It is often confused with metastases from other organs and does not respond well to standard ovarian cancer therapies. If MOC is more similar to mucinous cancers from other organs than other ovarian cancers, it may be better treated with chemotherapeutics that show success with other mucinous tumours.

Related publications (4)

A Refined Cut-Off for p53 Immunohistochemistry Improves Prediction of TP53 Mutation Status in Ovarian Mucinous Tumors: Implications for Outcome Analyses

Eun-Young Kang, Dane Cheasley, Cecile Le Page, Matthew Wakefield, Yoland Antill, Kylie Gorringe, Martin Kobel

2020-03-01

Therapeutic options for mucinous ovarian carcinoma

Kylie L Gorringe, Dane Cheasley, Matthew J Wakefield, Georgina L Ryland, Prue E Allan, Kathryn Alsop, Kaushalya C Amarasinghe, Sumitra Ananda, David DL Bowtell, Michael Christie, Yoke-Eng Chiew, Michael Churchman, Anna DeFazio, Sian Fereday, C Blake Gilks, Charlie Gourley, Alison M Hadley, Joy Hendley, Sally M Hunter, Scott H Kaufmann

2020-03-01

OBJECTIVE: Mucinous ovarian carcinoma (MOC) is an uncommon ovarian cancer histotype that responds poorly to conventional chemother..

The molecular origin and taxonomy of mucinous ovarian carcinoma

Dane Cheasley, Matthew J Wakefield, Georgina L Ryland, Prue E Allan, Kathryn Alsop, Kaushalya C Amarasinghe, Sumitra Ananda, Michael S Anglesio, George Au-Yeung, Maret Bohm, David Dl Bowtell, Alison Brand, Georgia Chenevix-Trench, Michael Christie, Yoke-Eng Chiew, Michael Churchman, Anna DeFazio, Renee Demeo, Rhiannon Dudley, Nicole Fairweather

2019-09-02